Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer.
Phase of Trial: Phase IV
Latest Information Update: 08 Dec 2015
At a glance
- Drugs Erlotinib (Primary) ; Cytokine-induced killer cell therapy; Dendritic cells
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Dec 2015 New trial record